Division Of Medication Error Prevention And Analysis Dmepa
Contents |
Home Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & Veterinary medication error definition Cosmetics Tobacco Products Drugs Home Drugs Drug Safety and Availability Medication medication errors statistics Errors Medication Errors Related to Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin medication errors in nursing it Email Print Within the Center for Drug Evaluation and Research (CDER), the Division of Medication Error Prevention and Analysis (DMEPA) reviews medication error reports on marketed human types of medication errors drugs including prescription drugs, generic drugs, and over-the-counter drugs. DMEPA uses the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) definition of a medication error. Specifically, a medication error is "any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the
Medication Errors Statistics 2015
health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use."DMEPA includes a medication error prevention program staffed with healthcare professionals. Among their many duties, program staff review medication error reports sent to MedWatch, evaluate causality, and analyze the data to provide solutions to reduce the risk of medication errors to industry and others at FDA.Additionally, DMEPA prospectively reviews proprietary names, labeling, packaging, and product design prior to drug approval to help prevent medication errors.Although DMEPA encourages manufacturers to perform their due diligence when naming their drug products and we strive to avoid approving confusing proprietary names for drug products, there are cases of adverse events where a name of a marketed product is identified as a source of confusion and error. Therefore, we continue to encourage healthcare providers, patients and consumers to report all medication errors to MedWat
joint effort between the Institute for Safe Medication Practices (ISMP) and the U.S. Food and Drug Administration
Preventing Medication Errors
(FDA), Center for Drug Evaluation and Research, Office of Surveillance examples of medication errors and Epidemiology, Division of Medication Error Prevention and Analysis (DMEPA). The fellow will spend 6 medication errors statistics 2014 months at ISMP in Horsham, PA, and 6 months at the FDA with DMEPA in Silver Spring, MD. The fellowship program gives experienced candidates http://www.fda.gov/drugs/drugsafety/medicationerrors/ an unparalleled opportunity to learn from and work with some of the nation’s top experts in medication safety. The fellow benefits from ISMP’s years of experience devoted to medication error prevention and safe medication use. At the FDA, valuable regulatory experience is gained by working with the division https://www.ismp.org/profdevelopment/fdaismpfellowship.asp focused on medication error prevention. HOW TO APPLY Applicants must submit the following to be considered: the application, a letter of interest, curriculum vitae, three professional and/or academic letters of reference, and official college transcripts. ISMP also has the "ISMP Safe Medication Management Fellowship." For more information on that fellowship program, click here. Resources Professional Development Main Page CE Opportunities Other continuing education opportunities Practitioner in Residence International Medication Safety Mentorship ISMP Safe Medication Management Fellowship FDA/ISMP Safe Medication Management Fellowship Home | Contact Us |Employment |Legal Notices| Privacy Policy | Help Support ISMP Med-ERRS | Medication Safety Officers Society | For consumers ISMP Canada| ISMP Spain | ISMP Brasil | International Group | Pennsylvania Patient Safety Authority 200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797, Fax: (215) 914-1492 © 2016 Institute for Safe Medication Practices. All rights reserved
Copyright, Trademark (Dr. Copyright is off this month - although some might say that he's always been a bit off - so http://garson-law.com/fda-division-medication-error-prevention-analysis/ our very own Dr. Trademark has stepped to the plate to hit more of your burning legal questions out of the park.) Dear Doc.: I was given a prescription for Noroxin to treat a UTI, but when I got back from Rite-Aid, the bottle they gave me contained Neurontin, which is used to treat epilepsy and pain. Somebody messed medication error up, and from what I read, this could have been very dangerous. Why can't someone keep this from happening by making sure that drug names are not confusingly similar? Signed, Confused Patient Dear Confused: Unlike regular trademarks for things like tractors, condoms and laundry detergent, names used on drugs are supposed to be unique, not confusing, and truthful. There of medication error is even an office at the US Food and Drug Administration (FDA) that is supposed to approve trademarks for drugs in an effort to prevent the over 1.3 million injuries each year that result from drug name confusion. Even though a drug company may be able to register a drug trademark with the Patent and Trademark Office (PTO), that does not mean that it will be approved by the FDA. The FDA's Division of Medication Error Prevention and Analysis (DMEPA) reviews all proposed names for confusing similarity to the names of other drugs or drug ingredients, including both trademarks and "established" or generic names. DMEPA typically rejects about one-third of all names reviewed. Some of the issues DMEPA hopes to avoid include names that suggest potentially exaggerated efficacy claims; names that could lead to erroneous prescriptions (e.g., wrong drug or dosage); and names that look or sound confusingly similar to other drug names. According to the FDA, there are some ways to reduce the risk that a name will be found misleading during approval: Avoi